EICHORCondition: Advanced Solid Tumors · Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This clinical study evaluated the efficacy and safety of T3011 in combination with PD-1/PD-L1 inhibitors in subjects with advanced solid tumors
This description comes directly from the study's public registry record.
Ye Guo · 0086-021-38804518 · pattrickguo@mail.com
Always discuss trial participation with your own doctor first.
| Anyang Cancer Hospital | Anyang, China | Recruiting |
| The First Affiliated Hospital of Bengbu Medical University | Bengbu, China | Recruiting |
| Hunan cancer hospital | Changsha, China | Recruiting |
| Sichuan Cancer Hospital | Chengdu, China | Recruiting |
| Dongguan People's Hospital | Dongwan, China | Recruiting |
| Fujian Cancer Hospital | Fuzhou, China | Recruiting |
| Sun Yat-sen Memorial Hospital, Sun Yat-sen University | Guangzhou, China | Recruiting |
| The First Affiliated Hospital of Guangdong Pharmaceutical University | Guangzhou, China | Recruiting |
| The First Affiliated Hospital, Zhejiang University School of Medicine | Hangzhou, China | Recruiting |
| The Second Affiliated Hospital of Zhejiang University School of Medicine | Hangzhou, China | Recruiting |
| Harbin Medical University Cancer Hospital | Ha’erbin, China | Recruiting |
| Shandong cancer hospital | Jinan, China | Recruiting |
+ 10 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06214143